Cargando…
BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens
MHC-I-associated peptides deriving from non-coding genomic regions and mutations can generate tumor-specific antigens, including neoantigens. Quantifying tumor-specific antigens’ RNA expression in malignant and benign tissues is critical for discriminating actionable targets. We present BamQuery, a...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426134/ https://www.ncbi.nlm.nih.gov/pubmed/37582761 http://dx.doi.org/10.1186/s13059-023-03029-1 |
_version_ | 1785089991472316416 |
---|---|
author | Cuevas, Maria Virginia Ruiz Hardy, Marie-Pierre Larouche, Jean-David Apavaloaei, Anca Kina, Eralda Vincent, Krystel Gendron, Patrick Laverdure, Jean-Philippe Durette, Chantal Thibault, Pierre Lemieux, Sébastien Perreault, Claude Ehx, Grégory |
author_facet | Cuevas, Maria Virginia Ruiz Hardy, Marie-Pierre Larouche, Jean-David Apavaloaei, Anca Kina, Eralda Vincent, Krystel Gendron, Patrick Laverdure, Jean-Philippe Durette, Chantal Thibault, Pierre Lemieux, Sébastien Perreault, Claude Ehx, Grégory |
author_sort | Cuevas, Maria Virginia Ruiz |
collection | PubMed |
description | MHC-I-associated peptides deriving from non-coding genomic regions and mutations can generate tumor-specific antigens, including neoantigens. Quantifying tumor-specific antigens’ RNA expression in malignant and benign tissues is critical for discriminating actionable targets. We present BamQuery, a tool attributing an exhaustive RNA expression to MHC-I-associated peptides of any origin from bulk and single-cell RNA-sequencing data. We show that many cryptic and mutated tumor-specific antigens can derive from multiple discrete genomic regions, abundantly expressed in normal tissues. BamQuery can also be used to predict MHC-I-associated peptides immunogenicity and identify actionable tumor-specific antigens de novo. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13059-023-03029-1. |
format | Online Article Text |
id | pubmed-10426134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104261342023-08-16 BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens Cuevas, Maria Virginia Ruiz Hardy, Marie-Pierre Larouche, Jean-David Apavaloaei, Anca Kina, Eralda Vincent, Krystel Gendron, Patrick Laverdure, Jean-Philippe Durette, Chantal Thibault, Pierre Lemieux, Sébastien Perreault, Claude Ehx, Grégory Genome Biol Method MHC-I-associated peptides deriving from non-coding genomic regions and mutations can generate tumor-specific antigens, including neoantigens. Quantifying tumor-specific antigens’ RNA expression in malignant and benign tissues is critical for discriminating actionable targets. We present BamQuery, a tool attributing an exhaustive RNA expression to MHC-I-associated peptides of any origin from bulk and single-cell RNA-sequencing data. We show that many cryptic and mutated tumor-specific antigens can derive from multiple discrete genomic regions, abundantly expressed in normal tissues. BamQuery can also be used to predict MHC-I-associated peptides immunogenicity and identify actionable tumor-specific antigens de novo. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13059-023-03029-1. BioMed Central 2023-08-15 /pmc/articles/PMC10426134/ /pubmed/37582761 http://dx.doi.org/10.1186/s13059-023-03029-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Method Cuevas, Maria Virginia Ruiz Hardy, Marie-Pierre Larouche, Jean-David Apavaloaei, Anca Kina, Eralda Vincent, Krystel Gendron, Patrick Laverdure, Jean-Philippe Durette, Chantal Thibault, Pierre Lemieux, Sébastien Perreault, Claude Ehx, Grégory BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
title | BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
title_full | BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
title_fullStr | BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
title_full_unstemmed | BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
title_short | BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
title_sort | bamquery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens |
topic | Method |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426134/ https://www.ncbi.nlm.nih.gov/pubmed/37582761 http://dx.doi.org/10.1186/s13059-023-03029-1 |
work_keys_str_mv | AT cuevasmariavirginiaruiz bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT hardymariepierre bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT larouchejeandavid bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT apavaloaeianca bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT kinaeralda bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT vincentkrystel bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT gendronpatrick bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT laverdurejeanphilippe bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT durettechantal bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT thibaultpierre bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT lemieuxsebastien bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT perreaultclaude bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens AT ehxgregory bamqueryaproteogenomictooltoexploretheimmunopeptidomeandprioritizeactionabletumorantigens |